Skip to main content
. 2024 Jul 16;20(24):1753–1764. doi: 10.1080/14796694.2024.2370186

Figure 3.

Figure 3.

First progression event in first 12 months of follow-up among patients with metastatic non-small-cell lung cancer epidermal growth factor receptor activating mutation following initiation of first-line treatment on an epidermal growth factor receptor tyrosine kinase inhibitor.

EGFRm: Epidermal growth factor receptor activating mutation; mNSCLC: Metastatic non-small-cell lung cancer; TKI: Tyrosine kinase inhibitor.